



DAFTAR PUSTAKA

- Alentorn, A., Duran-Peña, A., Pingle, S. C., Piccioni, D. E., Idbaih, A., & Kesari, S. (2015). Molecular profiling of gliomas: potential therapeutic implications. *Expert Review of Anticancer Therapy*, 15(8), 955–962. <https://doi.org/10.1586/14737140.2015.1062368>
- Baan, R., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Islami, F., Galichet, L., Straif, K., & WHO International Agency for Research on Cancer Monograph Working Group. (2011). Carcinogenicity of radiofrequency electromagnetic fields. *The Lancet Oncology*, 12(7), 624–626. [https://doi.org/10.1016/S1470-2045\(11\)70147-4](https://doi.org/10.1016/S1470-2045(11)70147-4)
- Beyer, S., Fleming, J., Meng, W., Singh, R., Haque, S. J., & Chakravarti, A. (2017). The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas. *Cancers*, 9(7). <https://doi.org/10.3390/CANCERS9070085>
- Birner, P., Pusch, S., Christov, C., Mihaylova, S., Toumangelova-Uzeir, K., Natchev, S., Schoppmann, S. F., Tchobanov, A., Streubel, B., Tuettenberg, J., & Guentchev, M. (2014). Mutant *IDH1* inhibits PI3K/Akt signaling in human glioma. *Cancer*, 120(16), 2440–2447. <https://doi.org/10.1002/CNCR.28732>
- Binjabal, D., al Majarafi, N., Pond, G. R., & Hirte, H. (2025). Incidence of Venous Thromboembolism in Newly Diagnosed Glioblastoma and Associated Risk Factors: A Retrospective Chart Review. *Current Oncology 2025, Vol. 32, Page 449*, 32(8), 449. <https://doi.org/10.3390/CURRONCOL32080449>
- Brandes, A. A., Gil-Gil, M., Saran, F., Carpentier, A. F., Nowak, A. K., Mason, W., Zagonel, V., Dubois, F., Finocchiaro, G., Fountzilias, G., Cernea, D. M., Chinot, O., Anghel, R., Ghiringhelli, F., Beauchesne, P., Lombardi, G., Franceschi, E., Makrutzki, M., Mpofo, C., ... Pichler, J. (2019). A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. *The Oncologist*, 24(4), 521–528. <https://doi.org/10.1634/THEONCOLOGIST.2018-0290>
- Brat, D. J., Aldape, K., Bridge, J. A., Canoll, P., Colman, H., Hameed, M. R., Harris, B. T., Hattab, E. M., Huse, J. T., Jenkins, R. B., Lopez-Terrada, D. H., McDonald, W. C., Rodriguez, F. J., Souter, L. H., Colasacco, C., Thomas, N. E., Hawks Yount, M., van den Bent, M. J., & Perry, A. (2022). Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. *Archives of Pathology & Laboratory Medicine*, 146(5), 547–574. <https://doi.org/10.5858/ARPA.2021-0295-CP>
- Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., Beroukhim, R., Bernard, B., Wu, C. J., Genovese, G., Shmulevich, I., Barnholtz-Sloan, J., Zou, L., Vegesna, R., Shukla, S. A., ... McLendon, R. (2013). The somatic genomic landscape of glioblastoma. *Cell*, 155(2), 462. <https://doi.org/10.1016/J.CELL.2013.09.034>



- Byun, Y. H., & Park, C.-K. (2022). Classification and Diagnosis of Adult Glioma: A Scoping Review. *Brain & NeuroRehabilitation*, 15(3), e23. <https://doi.org/10.12786/BN.2022.15.E23>
- Carrillo, J. A., Lai, A., Nghiemphu, P. L., Kim, H. J., Phillips, H. S., Kharbanda, S., Moftakhar, P., Lalaezari, S., Yong, W., Ellingson, B. M., Cloughesy, T. F., & Pope, W. B. (2012). Relationship between tumor enhancement, edema, *IDH1* mutational status, *MGMT* promoter methylation, and survival in glioblastoma. *AJNR. American Journal of Neuroradiology*, 33(7), 1349–1355. <https://doi.org/10.3174/AJNR.A2950>
- Chaichana, K. L., Martinez-Gutierrez, J. C., de La Garza-Ramos, R., Weingart, J. D., Olivi, A., Gallia, G. L., Lim, M., Brem, H., & Quinones-Hinojosa, A. (2013). Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. *Journal of Clinical Neuroscience*, 20(6), 818–823. <https://doi.org/10.1016/J.JOCN.2012.07.016>
- Chen, J. W., Zhou, C. F., & Lin, Z. X. (2015). The influence of different classification standards of age groups on prognosis in high-grade hemispheric glioma patients. *Journal of the Neurological Sciences*, 356(1–2), 148–152. <https://doi.org/10.1016/J.JNS.2015.06.036>
- Chen, T., Xiao, F., Yu, Z., Yuan, M., Xu, H., & Lu, L. (2021). Detection and Grading of Gliomas Using a Novel Two-Phase Machine Learning Method Based on MRI Images. *Frontiers in Neuroscience*, 15. <https://doi.org/10.3389/FNINS.2021.650629>
- Cohen, A. L., Holmen, S. L., & Colman, H. (2013). *IDH1* and *IDH2* Mutations in Gliomas. *Current Neurology and Neuroscience Reports*, 13(5), 345. <https://doi.org/10.1007/S11910-013-0345-4>
- Coureau, G., Bouvier, G., Lebailly, P., Fabbro-Peray, P., Gruber, A., Leffondre, K., Guillamo, J. S., Loiseau, H., Mathoulin-Pélissier, S., Salamon, R., & Baldi, I. (2014). Mobile phone use and brain tumours in the CERENAT case-control study. *Occupational and Environmental Medicine*, 71(7), 514–522. <https://doi.org/10.1136/OEMED-2013-101754>
- Davis, M. E. (2018). Epidemiology and Overview of Gliomas. *Seminars in Oncology Nursing*, 34(5), 420–429. <https://doi.org/10.1016/J.SONCN.2018.10.001>
- Diaz, M., Jo, J., Smolkin, M., Ratcliffe, S. J., & Schiff, D. (2021). Risk of Venous Thromboembolism in Grade II–IV Gliomas as a Function of Molecular Subtype. *Neurology*, 96(7), e1063. <https://doi.org/10.1212/WNL.0000000000011414>
- Fonseca, A., Solano, P., Ramaswamy, V., Tabori, U., Huang, A., Drake, J. M., Tsang, D. S., Laperriere, N., Bartels, U., Kulkarni, A. V., & Bouffet, E. (2021). Ventricular size determination and management of ventriculomegaly and hydrocephalus in patients with diffuse intrinsic pontine glioma: an institutional experience. *Journal of Neurosurgery*, 135(4), 1139–1145. <https://doi.org/10.3171/2020.10.JNS203257>
- Gerritsen, J. K. W., Zwarthoed, R. H., Kilgallon, J. L., Nawabi, N. L., Versyck, G., Jessurun, C. A. C., Pruijn, K. P., Fisher, F. L., Larivière, E., Solie, L., Mekary, R. A., Satoer, D. D., Schouten, J. W., Bos, E. M., Kloet, A., Tewarie, R. N., Smith, T. R., Dirven, C. M. F., De Vleeschouwer, S., ... Broekman, M. L. D. (2023). Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically



- important glioblastoma subgroups. *Neuro-Oncology*, 25(5), 958–972. <https://doi.org/10.1093/NEUONC/NOAC255>
- Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022). Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. *Cancer*, 128(1), 47–58. <https://doi.org/10.1002/CNCR.33918>
- Grimaldi, S., Harlay, V., Appay, R., Bequet, C., Petrirena, G., Campello, C., Barrié, M., Autran, D., Boissonneau, S., Graillon, T., Figarella-Branger, D., Nanni, I., Chinot, O., & Tabouret, E. (2022). Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients. *Journal of Neuro-Oncology*, 156(3), 615–623. <https://doi.org/10.1007/S11060-022-03943-7>.
- Halasz, L. M., Attia, A., Bradfield, L., Brat, D. J., Kirkpatrick, J. P., Laack, N. N., Lalani, N., Lebow, E. S., Liu, A. K., Niemeier, H. M., Palmer, J. D., Peters, K. B., Sheehan, J., Thomas, R. P., Vora, S. A., Wahl, D. R., Weiss, S. E., Yeboa, D. N., Zhong, J., & Shih, H. A. (2022). Radiation Therapy for *IDH-mutant* Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*, 12(5), 370–386. <https://doi.org/10.1016/J.PRRO.2022.05.004>
- Hardell, L., Carlberg, M., Söderqvist, F., & Mild, K. H. (2013). Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use. *International Journal of Oncology*, 43(6), 1833–1845. <https://doi.org/10.3892/IJO.2013.2111/HTML>
- Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E. C., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., & Stupp, R. (2005). *MGMT* gene silencing and benefit from temozolomide in glioblastoma. *The New England Journal of Medicine*, 352(10), 997–1003. <https://doi.org/10.1056/NEJM0A043331>
- Hoke, M., Dieckmann, K., Koppensteiner, R., Schillinger, M., Marosi, C., & Mlekusch, W. (2011). Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study. *Wiener Klinische Wochenschrift*, 123(7–8), 199–203. <https://doi.org/10.1007/S00508-011-1556-9>
- Hovman, F. R., Poulsen, F. R., Hansen, S., & Dahlrot, R. H. (2024). The risk of venous thromboembolism in adult patients with diffuse glioma: a nationwide population-based study. *Acta Oncologica (Stockholm, Sweden)*, 63, 887–892. <https://doi.org/10.2340/1651-226X.2024.40137>
- Jia, Z., Li, X., Yan, Y., Shen, X., Wang, J., Yang, H., Liu, S., Han, C., & Hu, Y. (2022). Exploring the relationship between age and prognosis in glioma: rethinking current age stratification. *BMC Neurology*, 22(1), 350. <https://doi.org/10.1186/S12883-022-02879-9>
- Karschnia, P., Vogelbaum, M. A., van den Bent, M., Cahill, D. P., Bello, L., Narita, Y., Berger, M. S., Weller, M., & Tonn, J. C. (2021). Evidence-based recommendations on categories for extent of resection in diffuse glioma. *European Journal of Cancer (Oxford, England : 1990)*, 149, 23–33. <https://doi.org/10.1016/J.EJCA.2021.03.002>



- Kim, Y. Z., Kim, C.-Y., & Lim, D. H. (2022). The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO. *Brain Tumor Research and Treatment*, *10*(2), 83–93. <https://doi.org/10.14791/BTRT.2022.0001>
- Komori, T. (2022). Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. *Laboratory Investigation*, *102*(2), 126–133. <https://doi.org/10.1038/s41374-021-00667-6>
- Koudriavtseva, T., Villani, V., Lorenzano, S., Giannarelli, D., di Domenico, E. G., Stefanile, A., Maschio, M., D’Agosto, G., Pimpinelli, F., Tanzilli, A., Galiè, E., & Pace, A. (2021). Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma. *EXCLI Journal*, *20*, 1152–1169. <https://doi.org/10.17179/EXCLI2021-3831>
- Krieg, S. M., Gomez-Pinedo, U., Nielsen, V. G., Conti, L., Mandoj, C., & Tomao, L. (2019). Coagulation in Brain Tumors: Biological Basis and Clinical Implications. *Frontiers in Neurology*, *10*, 181. <https://doi.org/10.3389/FNEUR.2019.00181>
- Lawrie, T. A., Gillespie, D., Dowswell, T., Evans, J., Erridge, S., Vale, L., Kernohan, A., & Grant, R. (2019). Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. *The Cochrane Database of Systematic Reviews*, *8*(8). <https://doi.org/10.1002/14651858.CD013047.PUB2>
- Lerner, A., Palmer, K., Champion, T., Millner, T. O., Scott, E., Lorimer, C., Paraskevopoulos, D., McKenna, G., Marino, S., Lewis, R., & Plowman, N. (2024). Gliomas in adults: Guidance on investigations, diagnosis, treatment and surveillance. *Clinical Medicine*, *24*(5), 100240. <https://doi.org/10.1016/J.CLINME.2024.100240>
- Lost, J., Verma, T., Jekel, L., von Reppert, M., Tillmanns, N., Merckaj, S., Cassinelli Petersen, G., Bahar, R., Gordem, A., Haider, M. A., Subramanian, H., Brim, W., Ikuta, I., Omuro, A., Marco Conte, G., Marquez-Nostra, B. V., Avesta, A., Bousabarah, K., Nabavizadeh, A., ... Aboian, M. (2023). Systematic Literature Review of Machine Learning Algorithms Using Pretherapy Radiologic Imaging for Glioma Molecular Subtype Prediction. *AJNR. American Journal of Neuroradiology*, *44*(10), 1126–1134. <https://doi.org/10.3174/AJNR.A8000>
- Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., Von Deimling, A., & Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology*, *23*(8), 1231. <https://doi.org/10.1093/NEUONC/NOAB106>
- Mandel, J. J., Youssef, M., Yust-Katz, S., Patel, A. J., Jalali, A., Li, Z., Wu, J., Ludmir, E. B., & de Groot, J. F. (2021). IDH mutation status and the development of venous thromboembolism in astrocytoma patients. *Journal of the Neurological Sciences*, *427*, 117538. <https://doi.org/10.1016/j.jns.2021.117538>
- McBain, C., Lawrie, T. A., Rogozińska, E., Kernohan, A., Robinson, T., & Jefferies, S. (2021). Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. *Cochrane Database of Systematic Reviews*, *2020*(12). https://doi.org/10.1002/14651858.CD013579.PUB2/MEDIA/CDSR/CD013579/IMAGE_T/TCDD013579-FIG-11.PNG



- McLendon, R., Friedman, A., Bigner, D., Van Meir, E. G., Brat, D. J., Mastrogianakis, G. M., Olson, J. J., Mikkelsen, T., Lehman, N., Aldape, K., Yung, W. K. A., Bogler, O., Weinstein, J. N., VandenBerg, S., Berger, M., Prados, M., Muzny, D., Morgan, M., Scherer, S., ... Thomson, E. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, *455*(7216), 1061. <https://doi.org/10.1038/NATURE07385>
- Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., ... Cloughesy, T. F. (2023). Vorasidenib in *IDH1*- or *IDH2*-Mutant Low-Grade Glioma. *New England Journal of Medicine*, *389*(7), 589–601. https://doi.org/10.1056/NEJMOA2304194/SUPPL_FILE/NEJMOA2304194_DATA-SHARING.PDF
- Mesfin, F. B., Karsonovich, T., & Al-Dhahir, M. A. (2024). Gliomas. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK441874/>
- Mir Seyed Nazari, P., Riedl, J., Preusser, M., Posch, F., Thaler, J., Marosi, C., Birner, P., Ricken, G., Hainfellner, J. A., Pabinger, I., & Ay, C. (2018). Combination of isocitrate dehydrogenase 1 (*IDH1*) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. *Journal of thrombosis and haemostasis : JTH*, *16*(6), 1121–1127. <https://doi.org/10.1111/jth.14129>
- Miller, J. J., Nicolas Gonzalez Castro, L., McBrayer, S., Weller, M., Cloughesy, T., Portnow, J., Andronesi, O., Barnholtz-Sloan, J. S., Baumert, B. G., Berger, M. S., Bi, W. L., Bindra, R., Cahill, D. P., Chang, S. M., Costello, J. F., Horbinski, C., Huang, R. Y., Jenkins, R. B., Ligon, K. L., ... Wen, P. Y. (2023). Isocitrate dehydrogenase (*IDH*) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. *Neuro-Oncology*, *25*(1), 4–25. <https://doi.org/10.1093/NEUONC/NOAC207>
- Muster, V., & Gary, T. (2021). Contrasts in Glioblastoma—Venous Thromboembolism versus Bleeding Risk. *Cells*, *10*(6), 1414. <https://doi.org/10.3390/CELLS10061414>
- Navone, S. E., Guarnaccia, L., Locatelli, M., Rampini, P., Caroli, M., la Verde, N., Gaudino, C., Bettinardi, N., Riboni, L., Marfia, G., & Campanella, R. (2019). Significance and Prognostic Value of The Coagulation Profile in Patients with Glioblastoma: Implications for Personalized Therapy. *World Neurosurgery*, *121*, e621–e629. <https://doi.org/10.1016/J.WNEU.2018.09.177>
- Neglia, J. P., Robison, L. L., Stovall, M., Liu, Y., Packer, R. J., Hammond, S., Yasui, Y., Kasper, C. E., Mertens, A. C., Donaldson, S. S., Meadows, A. T., & Inskip, P. D. (2006). New Primary Neoplasms of the Central Nervous System in Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor Study. *JNCI: Journal of the National Cancer Institute*, *98*(21), 1528–1537. <https://doi.org/10.1093/JNCI/DJJ411>
- Ohba, S., Teranishi, T., Matsumura, K., Kumon, M., Kojima, D., Fujiwara, E., Nakao, K., Kuwahara, K., Murayama, K., Pareira, E. S., Yamada, S., Joko, M., Nakae, S., Muto, J., Nishiyama, Y., Adachi, K., Sasaki, H., Abe, M., Hasegawa, M., & Hirose, Y. (2025).



- Factors involved in maintaining Karnofsky Performance Status ($\geq 50\%$) in glioblastoma, *IDH-wildtype* patients treated with temozolomide and radiotherapy. *Scientific Reports*, *15*(1). <https://doi.org/10.1038/S41598-025-85339-X>
- Osada, Y., Saito, R., Miyata, S., Shoji, T., Shibahara, I., Kanamori, M., Sonoda, Y., Kumabe, T., Watanabe, M., & Tominaga, T. (2021). Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma. *Brain Tumor Pathology*, *38*(3), 218–227. <https://doi.org/10.1007/s10014-021-00406-1>
- Oster, C., Schmidt, T., Agkatsev, S., Lazaridis, L., Kleinschnitz, C., Sure, U., Scheffler, B., Kebir, S., & Glas, M. (2023). Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022. *Neuro-Oncology Advances*, *5*(1). <https://doi.org/10.1093/NOAJNL/VDAD105>
- Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., Wrensch, M. R., & Barnholtz-Sloan, J. S. (2014). The epidemiology of glioma in adults: a “state of the science” review. *Neuro-Oncology*, *16*(7), 896. <https://doi.org/10.1093/NEUONC/NOU087>
- Ostrom, Q. T., Cote, D. J., Ascha, M., Kruchko, C., & Barnholtz-Sloan, J. S. (2018). Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. *JAMA Oncology*, *4*(9), 1254–1262. <https://doi.org/10.1001/JAMAONCOL.2018.1789>
- Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S. M., & Barnholtz-Sloan, J. S. (2015). Epidemiology of Gliomas. *Cancer Treatment and Research*, *163*, 1–14. https://doi.org/10.1007/978-3-319-12048-5_1
- Park, Y. W., Vollmuth, P., Foltyn-Dumitru, M., Sahm, F., Ahn, S. S., Chang, J. H., & Kim, S. H. (2023). The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1—Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas. *Journal of Magnetic Resonance Imaging*, *58*(3), 677–689. <https://doi.org/10.1002/JMRI.28743>
- Peeters, M. C. M., Dirven, L., Koekkoek, J. A. F., Gortmaker, E. G., Fritz, L., Vos, M. J., & Taphoorn, M. J. B. (2020). Prediagnostic symptoms and signs of adult glioma: the patients’ view. *Journal of Neuro-Oncology*, *146*(2), 293–301. <https://doi.org/10.1007/S11060-019-03373-Y>
- Penkova, A., Kuziakova, O., Gulaia, V., Tiasto, V., Goncharov, N. V., Lanskikh, D., Zhmenia, V., Baklanov, I., Farniev, V., & Kumeiko, V. (2023). Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects. *Frontiers in Molecular Biosciences*, *10*, 1216102. <https://doi.org/10.3389/FMOLB.2023.1216102/BIBTEX>
- Pöhlmann, J., Weller, M., Marcellusi, A., Grabe-Heyne, K., Krott-Coi, L., Rabar, S., & Pollock, R. F. (2024). High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma. *Frontiers in Oncology*, *14*. <https://doi.org/10.3389/FONC.2024.1368606/FULL>



- Rathore, S., Niazi, T., Iftikhar, M. A., & Chaddad, A. (2020). Glioma Grading via Analysis of Digital Pathology Images Using Machine Learning. *Cancers*, *12*(3). <https://doi.org/10.3390/cancers12030578>
- Ranger, A. M., Patel, Y. K., Chaudhary, N., & Anantha, R. V. (2014). Familial syndromes associated with intracranial tumours: A review. *Child's Nervous System*, *30*(1), 47–64. <https://doi.org/10.1007/S00381-013-2309-Z/METRICS>
- Rasmussen, B. K., Hansen, S., Laursen, R. J., Kosteljanetz, M., Schultz, H., Nørgård, B. M., Guldborg, R., & Gradel, K. O. (2017). Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. *Journal of Neuro-Oncology*, *135*(3), 571–579. <https://doi.org/10.1007/S11060-017-2607-5>
- Rennert, R. C., Brandel, M. G., Srinivas, S., Prajapati, D., Al Jammal, O. M., Brown, N. J., Diaz-Aguilar, L. D., Elster, J., Gonda, D. D., Crawford, J. R., & Levy, M. L. (2021). Palliative endoscopic third ventriculostomy for pediatric primary brain tumors: a single-institution case series. *Journal of Neurosurgery. Pediatrics*, *28*(4), 387–394. <https://doi.org/10.3171/2021.3.PEDS20952>
- Rodriguez, F. J., Vizcaino, M. A., & Lin, M. T. (2016). Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. *The Journal of Molecular Diagnostics : JMD*, *18*(5), 620–634. <https://doi.org/10.1016/J.JMOLDX.2016.05.005>
- Rožanov, I. D., Shirikov, E. I., Balkanov, A. S., Gaganov, L. E., & Vasilenko, I. A. (2017). Some features controlling the blood D-dimer level after resection of malignant brain glioma. *Zhurnal Voprosy Neirokhirurgii Imeni N.N. Burdenko*, *81*(6), 64–68. <https://doi.org/10.17116/NEIRO201781664-68>
- Stabellini, N., Krebs, H., Patil, N., Waite, K., & Barnholtz-Sloan, J. S. (2021). Sex Differences in Time to Treat and Outcomes for Gliomas. *Frontiers in Oncology*, *11*. <https://doi.org/10.3389/FONC.2021.630597>
- Tavelin, B., & Malmström, A. (2022). Sex Differences in Glioblastoma—Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018. *Journal of Clinical Medicine* 2022, Vol. 11, Page 486, *11*(3), 486. <https://doi.org/10.3390/JCM11030486>
- Torp, S. H., Solheim, O., & Skjulsvik, A. J. (2022). The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview. *Acta Neurochirurgica*, *164*(9), 2453. <https://doi.org/10.1007/S00701-022-05301-Y>
- Turkalp, Z., Karamchandani, J., & Das, S. (2014). IDH Mutation in Glioma: New Insights and Promises for the Future. *JAMA Neurology*, *71*(10), 1319–1325. <https://doi.org/10.1001/JAMANEUROL.2014.1205>
- Unruh, D., Schwarze, S. R., Khoury, L., Thomas, C., Wu, M., Chen, L., Chen, R., Liu, Y., Schwartz, M. A., Amidei, C., Kumthekar, P., Benjamin, C. G., Song, K., Dawson, C., Rispoli, J. M., Fatterpekar, G., Golfinos, J. G., Kondziolka, D., Karajannis, M., ... Horbinski, C. (2016). Mutant *IDH1* and Thrombosis in Gliomas. *Acta Neuropathologica*, *132*(6), 917. <https://doi.org/10.1007/S00401-016-1620-7>



- Wang, P., Hou, C. X., Li, Y. W., & Zhou, D. (2016). Dietary nitrite and nitrate is not associated with adult glioma risk: A meta-analysis. *International Journal of Clinical and Experimental Medicine*, 9(5), 8334–8340
- Wanis, H. A., Møller, H., Ashkan, K., & Davies, E. A. (2024). Association of *IDH1* Mutation and *MGMT* Promoter Methylation with Clinicopathological Parameters in an Ethnically Diverse Population of Adults with Gliomas in England. *Biomedicines*, 12(12). <https://doi.org/10.3390/BIOMEDICINES12122732>
- Weidl, D., Capper, D., Onken, J., Liu, I., Glaser, D., Orben, F., Eberle, K., Coburger, J., & Bullinger, L. (2025). Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany. *Journal of Neuro-Oncology*, 174(2), 391–400. <https://doi.org/10.1007/S11060-025-05068-Z>
- Weller, J., Katzendobler, S., Karschnia, P., Lietke, S., Egensperger, R., Thon, N., Weller, M., Suchorska, B., & Tonn, J. C. (2021). PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. *Journal of Neuro-Oncology*, 153(2), 283–291. <https://doi.org/10.1007/S11060-021-03765-Z>
- Wick, W., Weller, M., Van Den Bent, M., Sanson, M., Weiler, M., Von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014). *MGMT* testing—the challenges for biomarker-based glioma treatment. *Nature Reviews Neurology* 2014 10:7, 10(7), 372–385. <https://doi.org/10.1038/nrneuro.2014.100>.
- Yin, J., Liu, G., Zhang, Y., Zhou, Y., Pan, Y., Zhang, Q., Yu, R., & Gao, S. (2024). Gender differences in gliomas: From epidemiological trends to changes at the hormonal and molecular levels. *Cancer Letters*, 598. <https://doi.org/10.1016/J.CANLET.2024.217114>.
- Yu, J., Li, D., Lei, D., Yuan, F., Pei, F., Zhang, H., Yu, A., Wang, K., Chen, H., Chen, L., Wu, X., Tong, X., & Wang, Y. (2016). Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study. *PLoS ONE*, 11(11), e0165390. <https://doi.org/10.1371/JOURNAL.PONE.0165390>
- Zacher, A., Kaulich, K., Stepanow, S., Wolter, M., Köhrer, K., Felsberg, J., Malzkorn, B., & Reifenberger, G. (2017). Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel. *Brain Pathology (Zurich, Switzerland)*, 27(2), 146–159. <https://doi.org/10.1111/BPA.12367>
- Zhang, C., & Zhu, Q. X. (2017). Allergy is associated with reduced risk of glioma: A meta-analysis. *Allergologia et Immunopathologia*, 45(6), 553–559. <https://doi.org/10.1016/J.ALLER.2016.12.005>
- Zhang, S., Guo, M., Liu, Q., Liu, J., & Cui, Y. (2021). Neutrophil extracellular traps induce a hypercoagulable state in glioma. *Immunity, Inflammation and Disease*, 9(4), 1383. <https://doi.org/10.1002/IID3.488>
- Zhao, H., Cai, W., Su, S., Zhi, D., Lu, J., & Liu, S. (2014). Allergic conditions reduce the risk of glioma: A meta-analysis based on 128,936 subjects. *Tumor Biology*, 35(4), 3875–3880. <https://doi.org/10.1007/S13277-013-1514-4>